迈得医疗(688310) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥40,176,271.66, a decrease of 45.87% compared to ¥74,220,852.42 in the same period last year[3] - The net profit attributable to shareholders was -¥10,797,370.24, representing a decline of 202.7% from a profit of ¥10,513,161.20 in the previous year[3] - The basic earnings per share were -¥0.07, a decrease of 216.67% from ¥0.06 in the same period last year[3] - The diluted earnings per share also stood at -¥0.07, showing a decline of 216.67% compared to the previous year's ¥0.06[3] - The weighted average return on equity was -1.34%, a decrease of 2.51 percentage points from the previous year's 1.17%[3] - The net loss for Q1 2025 was CNY 13,352,887.54, compared to a net profit of CNY 9,614,159.23 in Q1 2024, indicating a significant decline in profitability[19] - The total equity attributable to shareholders decreased to CNY 784,825,447.22 in Q1 2025 from CNY 810,050,019.65 in Q1 2024, a decline of 3.1%[17] Cash Flow - The net cash flow from operating activities increased by 187.24% to ¥29,713,887.51, up from ¥10,344,617.70 in the same period last year[3] - Cash flow from operating activities for Q1 2025 was $29,713,887.51, a significant increase from $10,344,617.70 in Q1 2024, representing a growth of 187.5%[22] - Total cash inflow from investment activities in Q1 2025 was $146,353,661.00, compared to $5,330,784.87 in Q1 2024, indicating a substantial increase[22] - Net cash outflow from investment activities was -$35,241,358.69 in Q1 2025, worsening from -$23,828,213.47 in Q1 2024[23] - Cash flow from financing activities generated a net inflow of $4,822,770.54 in Q1 2025, compared to an inflow of $890,109.18 in Q1 2024[23] - The company reported a net cash increase of -$627,811.49 in Q1 2025, compared to -$12,378,088.04 in Q1 2024, showing an improvement in cash flow dynamics[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,088,739,539.60, reflecting a 3.35% increase from ¥1,053,411,101.81 at the end of the previous year[4] - Total liabilities rose to CNY 271,484,133.79 in Q1 2025, up from CNY 207,957,231.30 in Q1 2024, marking an increase of 30.6%[17] - The company's total assets increased to CNY 1,088,739,539.60 in Q1 2025 from CNY 1,053,411,101.81 in Q1 2024, representing a growth of 3.4%[17] Research and Development - Research and development expenses totaled ¥9,155,975.84, accounting for 22.79% of operating revenue, an increase of 9.48 percentage points from 13.31%[4] - Research and development expenses for Q1 2025 were CNY 9,155,975.84, slightly down from CNY 9,880,803.80 in Q1 2024, showing a decrease of 7.3%[18] Share Repurchase - As of March 31, 2025, the company has repurchased a total of 2,592,575 shares, accounting for 1.56% of the total share capital of 166,219,690 shares[12] - The total amount spent on share repurchase is RMB 29,156,636.67, with a maximum transaction price of RMB 13.45 per share and a minimum of RMB 9.30 per share[12] - The company plans to use repurchased shares for employee stock ownership plans or equity incentives, with a repurchase budget between RMB 15 million and RMB 30 million[11] Market Conditions - The decline in revenue and net profit was primarily attributed to fluctuations in downstream market demand and reduced customer investment willingness[6] Shareholder Information - The top ten shareholders hold a combined 47.15% of the shares, with Lin Junhua being the largest shareholder at 47.15%[9] - The company has not identified any related party relationships among the top ten shareholders, except for Lin Junhua's connection with Taizhou Saina Investment Consulting Partnership[10] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[10]